344079-M

Flurbiprofen

A mixture of S(+) and R(-) enantiomers.

• Sinônimo(s): Flurbiprofen, (±)-2-Fluoro-α-methyl[1,1ʹ-biphenyl]-4-acetic Acid, U-27182
• Fórmula empírica (Notação de Hill): C₁₅H₁₃FO₂
• Número CAS: 5104-49-4
• Peso molecular: 244.26
• Número MDL: MFCD00079303
• Código UNSPSC: 12352200

Propriedades

• Nível de qualidade: 100
• Ensaio: ≥98% (HPLC)
• Formulário: solid
• fabricante/nome comercial: Calbiochem^®
• condição de armazenamento: OK to freeze
• cor: white
• solubilidade: DMSO: 50 mg/mL
• temperatura de armazenamento: 10-30°C
• InChI: 1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)
• chave InChI: SYTBZMRGLBWNTM-UHFFFAOYSA-N

Descrição

Descrição geral

A mixture of S(+) and R(–) enantiomers. A cell-permeable, non-steroidal anti-inflammatory agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). Strongly inhibits insoluble transthyretin (TTR) amyloid fibril formation. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces microglial activation and β-amyloid deposit in APP+PS1 transgenic mice.

A mixture of S(+) and R(-) enantiomers. A cell-permeable, non-steroidal anti-inflammatory (NSAID) agent that acts as a potent inhibitor of cyclooxygenase (IC₅₀ = 5 nM for LPS-induced COX in human peripheral blood cells). The S(+) enantiomer is reported to be more potent as a COX-2 inhibitor than the R(-) enantiomer. Suppresses iNOS expression in RAW 264.7 macrophages. Reduces Aβ loads and Congo Red staining in APP+PS1 transgenic mice

Ações bioquímicas/fisiológicas

Primary Target
Cyclooxygenase

Target IC₅₀: 5 nM for LPS-induced COX

Advertência

Toxicity: Toxic & Carcinogenic / Teratogenic (G)

Reconstituição

Following reconstitution, aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at 4°C. Further dilution of stock solution in aqueous medium should be made just prior to use.

Outras notas

Jantzen, P.T., et al. 2002. J. Neurosci.22, 2246.
Hinz, R., et al. 2001. Pharmacol. Res.18, 151.
Klabunde, T., et al. 2000. Nat. Struct. Biol.7, 312.
Range, S.P., et al. 2000. Eur. Respir. J.15, 751.
van Haeringen, N.J., et al. 2000. J. Ocul. Pharmacol. Ther.16, 353.
Curnock, A.P., et al. 1997. J. Pharmacol. Exp. Ther.282, 339.
Reindeau, D., et al. 1997. Can. J. Physiol. Pharmacol.75, 1088.
Wechter, W.J., et al. 1997. Cancer Res. 57, 4316.
Karmali, R.A., and Marsh, J. 1986. Prostaglandins Leukot. Med. 23, 11.
Karmali, R.A., and Marsh, J. 1985. Prostaglandins Leukot. Med. 20, 283.

Informações legais

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Informações de segurança

• Pictogramas: GHS06
• Palavra indicadora: Danger
• Frases de perigo: H301
• Declarações de precaução: P264 - P270 - P301 + P310 - P405 - P501
• Classificações de perigo: Acute Tox. 3 Oral
• Código de classe de armazenamento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe de risco de água (WGK): WGK 3
• Ponto de fulgor (°F): Not applicable
• Ponto de fulgor (°C): Not applicable